2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-106863
    BRL 35135 86615-96-5 98%
    BRL 35135 is a potent and selective β3-adrenergic receptor agonist. BRL 35135 can dose dependently increase energy expenditure, reduce weight, and only reduce fat without reducing muscle protein. BRL 35135 can significantly improve glucose tolerance and insulin sensitivity. BRL 35135 can be used to study metabolic conditions such as obesity and diabetes.
    BRL 35135
  • HY-106867
    MKC-121 127754-47-6 98%
    MKC-121 is a compound with lipid-regulating activity and can be used in research on hyperlipidemia.
    MKC-121
  • HY-106877
    Minalrestat 129688-50-2 98%
    Minalrestat (ARI-509) is a potent and orally active aldose reductase inhibitor. Minalrestat can be used in the research of diabetes.
    Minalrestat
  • HY-106893
    Pimilprost 139403-31-9 98%
    Pimilprost (SM 10902) is a prostaglandin I1 analogue. Pimilprost exhibits antithrombotic and increases cAMP levels. Pimilprost can promote wound healing through the stimulation of angiogenesis and the improvement of blood flow in diabetic mice. Pimilprost can be used for the research of metabolic and cardiovascular disease, such as diabetes.
    Pimilprost
  • HY-106915
    SG-210 143162-65-6 98%
    SG-210 (SPR 210) is an orally active and selective aldose reductase (AR) inhibitor. SG-210 has IC50 values of 9.5 nM and 10 nM for AR from porcine lens and human placenta, respectively. SG-210 can inhibit sorbitol accumulation and ameliorate diabetic neuropathy and retinopathy in Streptozotocin (HY-13753)-induced diabetic rats. SG-210 can be used in the research of diseases such as diabetes-related complications.
    SG-210
  • HY-106938
    Eldacimibe 141993-70-6 98%
    Eldacimibe is an ACAT2 inhibitor. Eldacimibe can lower plasma cholesterol levels by blocking cholesterol absorption and can prevent macrophages from turning into foam cells. Eldacimibe can be used in the study of cardiovascular diseases (atherosclerosis), endocrine and metabolic diseases (hypercholesterolemia) .
    Eldacimibe
  • HY-106982
    Ezlopitant 147116-64-1 98%
    Ezlopitant (CJ-11,974) is a selective, non-peptidic neurokinin-1 (NK-1)-receptor antagonist. Ezlopitant inhibits both acute and delayed emetic reactions induced by Cisplatin (HY-17394) in ferrets via acting on NK1 receptors in the central nervous system. Ezlopitant has the potential for pain, chemotherapy-induced emesis and irritable bowel syndrome research.
    Ezlopitant
  • HY-107122
    MK-5932 1021539-02-5 98%
    MK-5932 is an orally active, selective, dissociated partial glucocorticoid receptor agonist. MK-5932 inhibits IL-6. MK-5932 induces lymphopenia. MK-5932 restores glucose levels to normal. MK-5932 shows anti-inflammatory effects.
    MK-5932
  • HY-107129
    MK-3577 1019112-29-8 98%
    MK-3577 is an orally effective glucagon receptor (GCGR) antagonist that reduces hepatic glucose production and lowers blood glucose levels by blocking glucagon receptors on target organs, primarily the liver. Pharmacokinetic analysis in domestic cats indicates that MK-3577 reaches peak levels 3 to 4 hours after oral administration, with a half-life of approximately 15 hours. MK-3577 can be used in diabetes research.
    MK-3577
  • HY-107169
    F-2875 109523-92-4 98%
    F-2875 is an orally active 2'-chloro 4-(chloroacetoxymethyl)biphenyl derivative. F-2875 can be used in the research of atherosclerosis.
    F-2875
  • HY-107176
    (E)-Hyzetimibe 1266548-75-7 98%
    (E)-Hyzetimibe ((E)-HS-25) (Compound I-1Z) is the trans isomer of Hyzetimibe (HY-107176A), a cholesterol-lowering agent. (E)-Hyzetimibe has cholesterol acyltransferase (ACTA) inhibitory activity, but its cholesterol-lowering effect is relatively weak. (E)-Hyzetimibe can inhibit the entry of hepatitis C virus (HCV) into host cells, and it has a synergistic effect when used in combination with interferon-α. (E)-Hyzetimibe can be used for the study of HCV infection.
    (E)-Hyzetimibe
  • HY-107217
    Apo-12'-lycopenal 1071-52-9 98%
    Apo-12'-lycopenal is a Lycopene (HY-N0287) metabolite. Apo-12'-lycopenal promotes adipocyte differentiation and adiponectin secretion via PPAR-γ activation.
    Apo-12'-lycopenal
  • HY-107317
    7-Keto-Naturalean 1449-61-2 98%
    7-Keto Naturalean (7-Keto-DHEA acetate) is a DHEA (HY-14650) analog and weight-loss agent. 7-Keto Naturalean not only exerts anti-aging effects, enhances immunity, improves brain function, boosts memory, prevents Alzheimer's disease, and stimulates the metabolism of hepatic active enzymes, especially thermogenic enzymes, but also functions to reduce fat mass and increase the density and vitality of bones and muscles.
    7-Keto-Naturalean
  • HY-107333
    Cinoxate 104-28-9 98%
    Cinoxate is a hypertrophic peroxisome proliferator activating receptor γ (PPARγ) agonist with Ki value of 18.0 μM. Cinoxate can be used to study obesity.
    Cinoxate
  • HY-107358
    Lidamidine 66871-56-5 98%
    Lidamidine (WHR-1142A free base) is an α2-adrenergic receptor agonist and antidiarrheal agent.
    Lidamidine
  • HY-107387
    PF-376304 851757-93-2 98%
    PF-376304 is an orally active non-specific class I phosphoinositide 3-kinase (PI3K) inhibitor with an IC50 of 0.197 μM against PI3Kγ. PF-376304 induces dose-dependent glucose and lipid metabolic disorders in rats, causes rapid death at high doses, and leads to metabolic abnormalities that are self-reversible at low doses. PF-376304 is applicable to the research of metabolic and inflammatory diseases.
    PF-376304
  • HY-107529
    TC-G 24 1257256-44-2 98%
    TC-G 24 (Compound 24) is a potent, selective glycogen synthase kinase-3β (GSK-3β) inhibitor with an IC50 of 17.1 nM. TC-G 24 can cross the BBB and can be used for studying many diseases such as type 2 diabetes mellitus, stroke, Alzheimer, and other related diseases.
    TC-G 24
  • HY-107530
    3F8 159109-11-2 98%
    3F8 is a potent and selective GSK-3β inhibitor that could be useful as new reagent and potential therapeutic candidate for GSK3 related diseases.
    3F8
  • HY-107567
    Carcinine 56897-53-1 98%
    Carcinine (β-Alanylhistamine) is a selective and orally active histamine H3 receptor antagonist with a Ki of 0.2939 μM. Carcinine can reduce histamine content. Carcinine exhibits anti-oxidant activity and neuroprotective effects. Carcinine shows positive inotropic effect and can reduce blood sugar and blood lipid levels. Carcinine can be used for the researches of inflammation, neurological, cardiovascular and metabolic disease, such as retinal damage, seizure and diabetes.
    Carcinine
  • HY-107612
    GPBAR-A 877052-79-4 98%
    GPBAR-A is a specific agonist of the bile acid receptor GPBAR1. GPBAR-A can be used for the research of diabetes mellitus.
    GPBAR-A
Cat. No. Product Name / Synonyms Application Reactivity